The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Bixlenvo
bictegravir/lenacapavir · BICTEGRAVIR SODIUM 75 mg/1; LENACAPAVIR SODIUM 50 mg/1 · Tablet, Film Coated · Oral · Gilead Sciences, Inc.
NDC 61958-3601-01 · 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC · NDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Regulatory
- Application
- NDA221104
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of bictegravir/lenacapavir (Tablet, Film Coated)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Gilead Sciences, Inc. | BICTEGRAVIR SODIUM 75 mg/1; LENACAPAVIR SODIUM 50 mg/1 | Sep 3, 2026 | Sep 3, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Bixlenvo — NDC 61958-3601-01," retrieved September 3, 2026, https://drugdashboards.com/drug/61958360101.
Free to cite with attribution — see how the data is put together.